Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Dexcom stock

DXCM
US2521311074
A0D9T1

Price

82.44
Today +/-
+4.21
Today %
+5.55 %

Dexcom stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Dexcom stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Dexcom stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Dexcom stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Dexcom's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Dexcom Stock Price History

DateDexcom Price
12/2/202482.44 undefined
11/29/202477.99 undefined
11/27/202478.10 undefined
11/26/202477.94 undefined
11/25/202477.89 undefined
11/22/202472.83 undefined
11/21/202474.46 undefined
11/20/202475.24 undefined
11/19/202474.88 undefined
11/18/202476.27 undefined
11/15/202475.88 undefined
11/14/202474.68 undefined
11/13/202472.38 undefined
11/12/202474.34 undefined
11/11/202470.31 undefined
11/8/202469.96 undefined
11/7/202468.91 undefined
11/6/202468.61 undefined
11/5/202469.00 undefined
11/4/202469.70 undefined

Dexcom Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Dexcom, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Dexcom from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Dexcom’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Dexcom. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Dexcom’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Dexcom’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Dexcom’s growth potential.

Dexcom Revenue, EBIT and net profit per share

DateDexcom RevenueDexcom EBITDexcom Net Income
2029e9.43 B undefined0 undefined0 undefined
2028e8.07 B undefined2.04 B undefined1.57 B undefined
2027e7.05 B undefined1.72 B undefined1.34 B undefined
2026e5.43 B undefined1.24 B undefined979.61 M undefined
2025e4.7 B undefined1.01 B undefined810.37 M undefined
2024e4.1 B undefined784.22 M undefined680.22 M undefined
20233.62 B undefined614.3 M undefined541.5 M undefined
20222.91 B undefined405.1 M undefined341.2 M undefined
20212.45 B undefined293.9 M undefined216.9 M undefined
20201.93 B undefined323.9 M undefined549.7 M undefined
20191.48 B undefined156.4 M undefined101.1 M undefined
20181.03 B undefined-186.3 M undefined-127.1 M undefined
2017718.5 M undefined-42.5 M undefined-50.2 M undefined
2016573.3 M undefined-63.9 M undefined-65.6 M undefined
2015402 M undefined-57.1 M undefined-57.6 M undefined
2014259.2 M undefined-21.5 M undefined-22.4 M undefined
2013160 M undefined-28.9 M undefined-29.8 M undefined
201299.9 M undefined-55.7 M undefined-54.5 M undefined
201176.3 M undefined-44.8 M undefined-44.7 M undefined
201048.6 M undefined-45.3 M undefined-55.2 M undefined
200929.7 M undefined-45.8 M undefined-53.5 M undefined
20089.8 M undefined-52.8 M undefined-58.9 M undefined
20074.6 M undefined-46.7 M undefined-48.5 M undefined
20062.2 M undefined-49.3 M undefined-46.6 M undefined
20050 undefined-32.4 M undefined-30.9 M undefined
20040 undefined-14.1 M undefined-17.2 M undefined

Dexcom Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000000000.010.030.050.080.10.160.260.40.570.721.031.481.932.452.913.624.14.75.437.058.079.43
-------100.00125.00222.2265.5258.3330.2661.6261.8855.2142.5425.3143.5943.1630.4927.1018.8324.5113.1114.7915.4629.9114.4316.84
-------400.00-200.00-55.5610.3437.5046.0546.4662.5067.9569.1565.9768.5264.3164.0267.7169.7765.2163.6456.2649.0142.4532.6828.5624.44
000000-0.01-0.01-0.0100.020.040.050.10.180.280.380.490.660.951.31.711.92.31000000
-0-0.01-0.01-0.01-0.02-0.03-0.05-0.05-0.06-0.05-0.06-0.04-0.05-0.03-0.02-0.06-0.07-0.05-0.130.10.550.220.340.540.680.810.981.341.570
-75.0042.8630.0030.7776.4753.334.3520.83-8.623.77-20.0022.73-46.30-24.14159.0914.04-23.08154.00-179.53443.56-60.6657.8758.6525.6919.1220.8636.5717.58-
6.97.68.28.79.175.8108.9113.3117.9177.4227.5262.3274.8284.4300.8319.2334.4345.2352.8369.2420.4428.8427.5425.5000000
------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Dexcom Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Dexcom is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (B)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                         
0.020.030.050.050.060.030.030.050.080.050.050.080.120.120.551.391.532.712.732.462.72
0000.10.21.13.56.712.519.526.142.474.1101.7134.3226.7286.3428.5514.3713.3973.9
0000000000000000000013.6
0001.41.12.42.68.18.27.491635.245.445.270.7119.8234.7357.3306.7559.6
0.100.51.31.61.42.83.51.823.43.96.89.216.616.53053.981.6192.6154.7
0.020.030.050.060.070.030.040.070.10.080.090.150.230.280.741.71.973.423.683.674.43
000.010.010.010.010.010.010.020.020.020.030.050.110.150.180.390.610.891.141.18
000000000000000000000
000000000000000000000
0000000004.23.62.72.20.2000031.5173.3134.5
0000000003.23.23.23.711.312.118.718.619.326.525.725.2
00.20.31.13.35.73.6112.11.91.60.11.91.714.714.2237.8301388.3494.4
000.010.010.010.010.010.010.020.030.030.040.060.120.160.220.430.871.251.721.84
0.020.030.060.060.080.040.050.080.120.110.120.180.290.40.91.922.44.294.935.396.26
                                         
52.477000000.10.10.100.10.10.10.10.10.10.10.10.40.4
00.010.130.190.180.220.270.410.50.520.560.640.780.911.091.561.682.132.112.263.51
-0.04-0.05-0.08-0.13-0.18-0.24-0.29-0.35-0.39-0.45-0.48-0.5-0.56-0.62-0.67-0.8-0.7-0.20.140.481.02
0-2.6-1.1000.10-0.1-0.1-0.10-0.1-0.3-1-2.61.52.33.20.5-11.6-16.7
000000000000000000000
0.020.030.050.060.01-0.02-0.020.060.10.080.080.140.220.280.420.760.981.932.252.734.52
0.70.41.60.81.51.12.61.82.83.94.29.91924.546.775.5102.3163.3189.4237.9276.4
000.0100.010.010.010.010.010.010.030.030.040.080.090.140.260.440.510.811.25
000006.47.73.51.61.40.70.70.80.93.22.91.72.217.110.125.9
000000000000000000000
0000.91.41.90.90.500.22.22.32.30000.68.80776.84.7
000.010.010.010.020.020.020.010.020.030.040.070.10.140.220.360.610.721.841.56
00000.060.040.05000.010000.010.331.021.071.722.041.262.49
0000000000000000005.94.90
00.10.20.40.76.60.811.22.71.71.53.910.611.512.778.1128.7125.7158.4147.1
00000.060.050.05000.010.01000.020.351.031.151.852.171.422.64
000.010.010.070.060.070.020.020.030.040.040.070.120.481.251.512.462.893.264.2
0.020.030.060.060.080.040.050.080.120.110.120.180.290.40.92.022.54.395.145.998.72
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Dexcom provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Dexcom's financial health and stability.

Assets

Dexcom's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Dexcom must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Dexcom after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Dexcom's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-7-9-13-30-46-48-58-53-55-44-54-29-22-57-65-50-127101493154341541
0001223223678101516294867102155186
000000000000000000-277-4-21-55
0005-536-2-9-3-3-2-12-24-62-406-20-132263
000158122229273752100202223229364261332436293223
000001320000000231010111212
000000000000000124316114212
-7-9-12-22-43-33-37-39-42-30-33223495692123314475442669748
00-1-4-3-3-2-3-6-8-9-7-16-33-55-66-67-180-199-389-364-236
-87-1-18-26-824-14-25-462820-16-51-55-144-139-1,015-1,018-216-521-507
-770-13-23-526-11-18-3837280-180-78-72-835-819173-156-270
0000000000000000000000
00003451-10060-2-2-2389617090600443
290215048014670743122419101094111520-535-662
2902150514624469741011211683997101091210-552-318
-----------------1.00-1.00-9.00-9.00-17.00-99.00
0000000000000000000000
14-279-195-10-91-253528148347695-690371235-410-75
-7.3-9.9-14.2-27.3-47.1-36.6-40-42.4-49.6-38.1-42.6-5.57.415.70.52656.1134.5276.653.3304.7511.9
0000000000000000000000

Dexcom stock margins

The Dexcom margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dexcom. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dexcom.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Dexcom's sales revenue. A higher gross margin percentage indicates that the Dexcom retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Dexcom's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Dexcom's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Dexcom's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Dexcom. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Dexcom's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Dexcom Margin History

Dexcom Gross marginDexcom Profit marginDexcom EBIT marginDexcom Profit margin
2029e63.65 %0 %0 %
2028e63.65 %25.24 %19.48 %
2027e63.65 %24.31 %18.96 %
2026e63.65 %22.85 %18.04 %
2025e63.65 %21.37 %17.23 %
2024e63.65 %19.14 %16.6 %
202363.65 %16.96 %14.95 %
202265.19 %13.92 %11.73 %
202169.78 %12 %8.86 %
202067.71 %16.81 %28.53 %
201964.07 %10.6 %6.85 %
201864.36 %-18.06 %-12.32 %
201768.49 %-5.92 %-6.99 %
201666 %-11.15 %-11.44 %
201569.25 %-14.2 %-14.33 %
201468.02 %-8.29 %-8.64 %
201362.56 %-18.06 %-18.63 %
201246.65 %-55.76 %-54.55 %
201146.92 %-58.72 %-58.58 %
201037.86 %-93.21 %-113.58 %
200912.46 %-154.21 %-180.13 %
2008-56.12 %-538.78 %-601.02 %
2007-176.09 %-1,015.22 %-1,054.35 %
2006-400 %-2,240.91 %-2,118.18 %
200563.65 %0 %0 %
200463.65 %0 %0 %

Dexcom Stock Sales Revenue, EBIT, Earnings per Share

The Dexcom earnings per share therefore indicates how much revenue Dexcom has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Dexcom earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Dexcom's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Dexcom’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Dexcom's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Dexcom Revenue, EBIT and net profit per share

DateDexcom Sales per ShareDexcom EBIT per shareDexcom Earnings per Share
2029e24.14 undefined0 undefined0 undefined
2028e20.67 undefined0 undefined4.03 undefined
2027e18.06 undefined0 undefined3.42 undefined
2026e13.9 undefined0 undefined2.51 undefined
2025e12.04 undefined0 undefined2.07 undefined
2024e10.49 undefined0 undefined1.74 undefined
20238.51 undefined1.44 undefined1.27 undefined
20226.81 undefined0.95 undefined0.8 undefined
20215.71 undefined0.69 undefined0.51 undefined
20204.58 undefined0.77 undefined1.31 undefined
20194 undefined0.42 undefined0.27 undefined
20182.92 undefined-0.53 undefined-0.36 undefined
20172.08 undefined-0.12 undefined-0.15 undefined
20161.71 undefined-0.19 undefined-0.2 undefined
20151.26 undefined-0.18 undefined-0.18 undefined
20140.86 undefined-0.07 undefined-0.07 undefined
20130.56 undefined-0.1 undefined-0.1 undefined
20120.36 undefined-0.2 undefined-0.2 undefined
20110.29 undefined-0.17 undefined-0.17 undefined
20100.21 undefined-0.2 undefined-0.24 undefined
20090.17 undefined-0.26 undefined-0.3 undefined
20080.08 undefined-0.45 undefined-0.5 undefined
20070.04 undefined-0.41 undefined-0.43 undefined
20060.02 undefined-0.45 undefined-0.43 undefined
20050 undefined-0.43 undefined-0.41 undefined
20040 undefined-1.55 undefined-1.89 undefined

Dexcom business model

Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom is one of the most popular companies on Eulerpool.com.

Dexcom Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Dexcom Revenue by Segment

DateInternationalOutside of the United StatesUnited States
2023997 M USD-2.63 B USD
2022-767.8 M USD2.14 B USD
2021-599.1 M USD1.85 B USD
2020-417.2 M USD1.51 B USD
2019-314.5 M USD1.16 B USD
2018-213.2 M USD818.4 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Dexcom Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Dexcom historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Dexcom shares outstanding

The number of shares was Dexcom in 2023 — This indicates how many shares 425.5 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Dexcom earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Dexcom's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Dexcom’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Dexcom's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Dexcom stock splits

In Dexcom's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Dexcom.

Dexcom latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.44 0.45  (1.51 %)2024 Q3
6/30/20240.39 0.43  (9.25 %)2024 Q2
3/31/20240.28 0.32  (16.15 %)2024 Q1
12/31/20230.44 0.5  (13.61 %)2023 Q4
9/30/20230.35 0.5  (43.84 %)2023 Q3
6/30/20230.23 0.34  (47.38 %)2023 Q2
3/31/20230.15 0.17  (13.79 %)2023 Q1
12/31/20220.28 0.34  (22.39 %)2022 Q4
9/30/20220.25 0.28  (13.54 %)2022 Q3
6/30/20220.19 0.17  (-12.14 %)2022 Q2
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Dexcom stock

Eulerpool World ESG Rating (EESG©)

54/ 100

🌱 Environment

42

👫 Social

65

🏛️ Governance

53

Environment

Scope 1 - Direct Emissions
5,383
Scope 2 - Indirect emissions from purchased energy
24,279
Scope 3 - Indirect emissions within the value chain
1,367
Total CO₂ emissions
29,662
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees48.95
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Dexcom shareholders

%
Name
Stocks
Change
Date
11.86572 % The Vanguard Group, Inc.46,347,4891,907,9516/30/2024
6.01429 % BlackRock Institutional Trust Company, N.A.23,491,8321,189,6756/30/2024
4.17529 % State Street Global Advisors (US)16,308,68293,8646/30/2024
3.92369 % Baillie Gifford & Co.15,325,931-362,4656/30/2024
3.05825 % Capital Research Global Investors11,945,527-1,490,3656/30/2024
2.71544 % Sands Capital Management, LLC10,606,503-290,2616/30/2024
2.48937 % Geode Capital Management, L.L.C.9,723,468545,2736/30/2024
2.43088 % Fidelity Management & Research Company LLC9,495,027470,3986/30/2024
2.12750 % Capital World Investors8,310,007237,8776/30/2024
1.99011 % Invesco Capital Management (QQQ Trust)7,773,36395,7749/30/2024
1
2
3
4
5
...
10

Dexcom Executives and Management Board

Mr. Kevin Sayer

(65)
Dexcom Chairman of the Board, President, Chief Executive Officer (since 2007)
Compensation 15.44 M

Mr. Michael Brown

(53)
Dexcom Executive Vice President, Chief Legal Officer
Compensation 5.75 M

Mr. Paul Flynn

(54)
Dexcom Executive Vice President - Global Revenue
Compensation 4.87 M

Mr. Jacob Leach

(45)
Dexcom Executive Vice President, Chief Operating Officer
Compensation 4.43 M

Mr. Girish Naganathan

(46)
Dexcom Executive Vice President, Chief Technology Officer
Compensation 4.05 M
1
2
3
4
...
5

Dexcom Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Tandem Diabetes Care Stock
Tandem Diabetes Care
SupplierCustomer0,910,960,950,890,800,82
Owens & Minor, Inc. Stock
Owens & Minor, Inc.
SupplierCustomer0,830,550,820,62-0,090,35
Alphabet Inc. Stock
Alphabet Inc.
SupplierCustomer0,820,790,850,830,850,68
Teladoc Health Stock
Teladoc Health
SupplierCustomer0,770,780,890,840,53-0,31
Ypsomed Holding Stock
Ypsomed Holding
SupplierCustomer0,54-0,190,720,670,450,49
OptimizeRx Corporation Stock
OptimizeRx Corporation
SupplierCustomer0,360,830,810,780,810,69
AmerisourceBergen Corporation Stock
AmerisourceBergen Corporation
SupplierCustomer0,32-0,030,34-0,39-0,460,28
McKesson Stock
McKesson
SupplierCustomer0,17-0,67-0,19-0,50-0,490,21
Rockley Photonics Stock
Rockley Photonics
SupplierCustomer0,070,670,750,770,32-0,30
Alphabet A Stock
Alphabet A
SupplierCustomer-0,110,810,790,710,640,65
1

Most common questions regarding Dexcom

What values and corporate philosophy does Dexcom represent?

Dexcom Inc is a reputable company that stands for a set of core values and a strong corporate philosophy. This company believes in providing innovative and life-changing continuous glucose monitoring (CGM) solutions for people with diabetes. Dexcom Inc consistently focuses on delivering accurate and reliable CGM technology, enhancing the lives of individuals managing this chronic condition. With a dedication to improving patient outcomes and quality of life, Dexcom Inc prioritizes patient safety, accessibility, and empowering individuals to make informed decisions about their health. Dexcom Inc's commitment to excellence and patient-centric approach has positioned it as a leader in the field of CGM technology.

In which countries and regions is Dexcom primarily present?

Dexcom Inc is primarily present in several countries and regions worldwide. The company operates in the United States, Canada, Europe, including the United Kingdom, Germany, France, Italy, Spain, and Sweden. Dexcom Inc also has a significant presence in Australia and New Zealand, as well as in parts of Asia, such as Japan and South Korea. Additionally, Dexcom Inc has been expanding its reach to other global markets to provide its innovative continuous glucose monitoring systems and diabetes management solutions to a broader customer base.

What significant milestones has the company Dexcom achieved?

Dexcom Inc has achieved several significant milestones in its corporate history. First, the company introduced the first continuous glucose monitoring (CGM) system, Dexcom STS, which revolutionized diabetes management. They further enhanced the technology with the release of Dexcom Seven Plus CGM system, offering improved accuracy and ease-of-use. Dexcom later introduced the Dexcom G4 Platinum CGM, setting new industry standards with enhanced sensor performance. Another notable milestone was the launch of Dexcom G5 Mobile CGM system, providing real-time glucose monitoring on a mobile device without the need for a separate receiver. These accomplishments reflect Dexcom Inc's commitment to improving the lives of individuals with diabetes through innovative CGM solutions.

What is the history and background of the company Dexcom?

Dexcom Inc is a leading medical device manufacturing company based in San Diego, California. Established in 1999, Dexcom has revolutionized diabetes management with their continuous glucose monitoring (CGM) systems. Dexcom's advanced CGM systems provide real-time glucose readings, helping diabetes patients effectively manage their condition. Over the years, the company has pioneered innovative technologies and received regulatory approvals for their life-saving products. Dexcom's commitment to improving the lives of people with diabetes has earned them a strong reputation in the medical industry. With a dedicated team of professionals, Dexcom continues to make remarkable advancements in CGM technology, offering improved accuracy and user-friendly features to enhance patients' quality of life.

Who are the main competitors of Dexcom in the market?

The main competitors of Dexcom Inc in the market include Abbott Laboratories, Medtronic, and Tandem Diabetes Care.

In which industries is Dexcom primarily active?

Dexcom Inc is primarily active in the healthcare and medical devices industry.

What is the business model of Dexcom?

Dexcom Inc's business model revolves around the development and distribution of continuous glucose monitoring systems. The company specializes in providing innovative medical devices and software solutions to monitor glucose levels in individuals with diabetes. Dexcom's products enable patients and healthcare professionals to make accurate, real-time glucose management decisions, contributing to improved diabetes management and overall patient outcomes. Dexcom Inc's commitment to technological advancements and medical innovation has positioned the company as a market leader in the field of continuous glucose monitoring.

What is the P/E ratio of Dexcom 2024?

The Dexcom P/E ratio is 51.57.

What is the P/S ratio of Dexcom 2024?

The Dexcom P/S ratio is 8.56.

What is the Quality Investing of Dexcom?

The Quality Investing for Dexcom is 6/10.

What is the revenue of Dexcom 2024?

The expected Dexcom revenue is 4.1 B USD.

How high is the profit of Dexcom 2024?

The expected Dexcom profit is 680.22 M USD.

What is the business model of Dexcom

Dexcom Inc. is an innovative company in the medical technology industry, specializing in the production of continuous glucose monitoring (CGM) systems for diabetes patients. Dexcom Inc. was founded in 1999 and is headquartered in San Diego, California. Dexcom's core business is the production of CGM systems. These systems allow diabetics to continuously monitor their blood sugar levels without having to regularly take blood samples. Dexcom's CGM systems use tiny sensors that are implanted under the skin to extract glucose levels from tissue. This data is transmitted to a wearable receiver or smartphone, allowing real-time monitoring of glucose levels. Dexcom's CGM systems have been developed for people with type 1 diabetes, type 2 diabetes, and gestational diabetes. In addition to the sensors, Dexcom also offers wearable receivers that allow monitoring of glucose levels at any time and anywhere. Dexcom's systems are FDA certified and have the CE Mark, indicating that they comply with strict safety and efficacy requirements. In addition to its core activity in CGM manufacturing, Dexcom also offers a range of support services for diabetes patients. These include training programs to facilitate the use of CGM systems and a customer support team available 24/7. Furthermore, the company recently entered into a partnership with Apple, allowing the Dexcom app to be downloaded on the Apple Watch, making it even easier to keep track of glucose levels. This collaboration is another step for Dexcom in improving technology and making the use of CGM systems more user-friendly. In terms of its business model, Dexcom earns money through the sale of CGM systems and accessories, as well as by providing support services. The company has an extensive distribution network and is also highly active internationally. Overall, the innovative company Dexcom Inc. has revolutionized the diabetes market with its continuous glucose monitoring. Dexcom Inc. has proven itself as a competent and trustworthy partner for diabetes patients and will continue to make a significant contribution to combating this disease.

What is the Dexcom dividend?

Dexcom pays a dividend of 0 USD distributed over payouts per year.

How often does Dexcom pay dividends?

The dividend cannot currently be calculated for Dexcom or the company does not pay out a dividend.

What is the Dexcom ISIN?

The ISIN of Dexcom is US2521311074.

What is the Dexcom WKN?

The WKN of Dexcom is A0D9T1.

What is the Dexcom ticker?

The ticker of Dexcom is DXCM.

How much dividend does Dexcom pay?

Over the past 12 months, Dexcom paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dexcom is expected to pay a dividend of 0 USD.

What is the dividend yield of Dexcom?

The current dividend yield of Dexcom is .

When does Dexcom pay dividends?

Dexcom pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Dexcom?

Dexcom paid dividends every year for the past 0 years.

What is the dividend of Dexcom?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Dexcom located?

Dexcom is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dexcom kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dexcom from 12/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/2/2024.

When did Dexcom pay the last dividend?

The last dividend was paid out on 12/2/2024.

What was the dividend of Dexcom in the year 2023?

In the year 2023, Dexcom distributed 0 USD as dividends.

In which currency does Dexcom pay out the dividend?

The dividends of Dexcom are distributed in USD.

All fundamentals about Dexcom

Our stock analysis for Dexcom Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dexcom Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.